^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | indoximod (NLG8189) (IDO inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial
Published date:
11/05/2020
Excerpt:
To assess clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane….A taxane (paclitaxel [80 mg/m2] weekly 3 weeks on, 1 week off, or docetaxel [75 mg/m2] every 3 weeks) plus placebo or indoximod (1200 mg) orally twice daily as first-line treatment....This randomized clinical trial found that, among patients with ERBB2-negative metastatic breast cancer, addition of indoximod to a taxane did not improve PFS compared with a taxane alone.
Secondary therapy:
paclitaxel; docetaxel
DOI:
10.1001/jamaoncol.2020.5572
Trial ID:
